HIV-1 Reverse Transcriptase Structure with RNase H Inhibitor Dihydroxy Benzoyl Naphthyl Hydrazone Bound at a Novel Site
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The rapid emergence of drug-resistant variants of human immunodeficiency virus, type 1 (HIV-1), has limited the efficacy of anti-acquired immune deficiency syndrome (AIDS) treatments, and new lead compounds that target novel binding sites are needed. We have determined the 3.15 A resolution crystal structure of HIV-1 reverse transcriptase (RT) complexed with dihydroxy benzoyl naphthyl hydrazone (DHBNH), an HIV-1 RT RNase H (RNH) inhibitor (RNHI). DHBNH is effective against a variety of drug-resistant HIV-1 RT mutants. While DHBNH has little effect on most aspects of RT-catalyzed DNA synthesis, at relatively high concentrations it does inhibit the initiation of RNA-primed DNA synthesis. Although primarily an RNHI, DHBNH binds >50 A away from the RNH active site, at a novel site near both the polymerase active site and the non-nucleoside RT inhibitor (NNRTI) binding pocket. When DHBNH binds, both Tyr181 and Tyr188 remain in the conformations seen in unliganded HIV-1 RT. DHBNH interacts with conserved residues (Asp186, Trp229) and has substantial interactions with the backbones of several less well-conserved residues. On the basis of this structure, we designed substituted DHBNH derivatives that interact with the NNRTI-binding pocket. These compounds inhibit both the polymerase and RNH activities of RT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., & Steitz, T. A. (1992) · Science · doi:10.1126/science.1377403 · Cited by 1,914 · cited 2×
“These comprise four polymerase subdomains: the thumb, palm, fingers, and connection (3, 4).”
BackgroundJacobo-Molina, A., Ding, J., Nanni, R. G., Clark, A. D., Lu, X., Tantillo, C., Williams, R. L., Kamer, G., Ferris, A. L., Clark, P., et al. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.6320 · Cited by 1,115
Self-citationKeck, J. L., & Marqusee, S. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2740 · Cited by 52
Research works printed but not linked: 48
- Coffin, 1997, Retroviruses
- Tisdale, 1991, Mutations within the RNase H domain of HIV-1 RT abolish virus infectivity, J. Gen. Virol., 72, 59, 10.1099/0022-1317-72-1-59 · DOI · Paper page
- Huang, 1998, Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance, Science, 282, 1669, 10.1126/science.282.5394.1669 · DOI · Paper page
- Sarafianos, 2001, Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA, EMBO J., 20, 1449, 10.1093/emboj/20.6.1449 · DOI · Paper page
- Rittinger, 1995, Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors, Proc. Natl. Acad. Sci. U.S.A., 92, 8046, 10.1073/pnas.92.17.8046 · DOI · Paper page
- Spence, 1995, Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors, Science, 267, 988, 10.1126/science.7532321 · DOI · Paper page
- Rodgers, 1995, The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1, Proc. Natl. Acad. Sci. U.S.A., 92, 1222, 10.1073/pnas.92.4.1222 · DOI · Paper page
- Hsiou, 1996, Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: Implications of conformational changes for polymerization and inhibition mechanisms, Structure, 4, 853, 10.1016/S0969-2126(96)00091-3 · DOI · Paper page
- Tantillo, 1994, Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: implications for mechanisms of drug inhibition and resistance, J. Mol. Biol., 243, 369, 10.1006/jmbi.1994.1665 · DOI · Paper page
- Das, 1996, Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant, J. Mol. Biol., 264, 1085, 10.1006/jmbi.1996.0698 · DOI · Paper page
- Esnouf, 1995, Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors, Nat. Struct. Biol., 2, 303, 10.1038/nsb0495-303 · DOI · Paper page
- Ding, 1997, Structural studies of HIV-1 reverse transcriptase and implications for drug design, 41
- Ding, 1998, Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template–primer and an antibody Fab fragment at 2.8 Å resolution, J. Mol. Biol., 284, 1095, 10.1006/jmbi.1998.2208 · DOI · Paper page
- Palaniappan, 1995, Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase, J. Biol. Chem., 270, 4861, 10.1074/jbc.270.9.4861 · DOI · Paper page
- Shaw-Reid, 2005, Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities, Biochemistry, 44, 1595, 10.1021/bi0486740 · DOI · Paper page
- Gopalakrishnan, 1994, Effect of a thiobenzimidazolone derivative on DNA strand transfer catalyzed by HIV-1 reverse transcriptase, J. Biol. Chem., 269, 4110, 10.1016/S0021-9258(17)41750-9 · DOI
- Sarafianos, 2004, Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases, Curr. Opin. Struct. Biol., 14, 716, 10.1016/j.sbi.2004.10.013 · DOI
- Borkow, 1997, Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone, Biochemistry, 36, 3179, 10.1021/bi9624696 · DOI · Paper page
- Sluis-Cremer, 2002, Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors, Mol. Pharmacol., 62, 398, 10.1124/mol.62.2.398 · DOI
- Shaw-Reid, 2003, Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid, J. Biol. Chem., 278, 2777, 10.1074/jbc.C200621200 · DOI · Paper page
- Ding, 1995, Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse non-nucleoside inhibitors, Nat. Struct. Biol., 2, 407, 10.1038/nsb0595-407 · DOI · Paper page
- Ren, 1995, High resolution structures of HIV-1 RT from four RT-inhibitor complexes, Nat. Struct. Biol., 2, 293, 10.1038/nsb0495-293 · DOI · Paper page
- Allen, 2002, The Cambridge Structural Database: A quarter of a million crystal structures and rising, Acta Crystallogr. B, 58, 380, 10.1107/S0108768102003890 · DOI · Paper page
- Pata, 2004, Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors, Proc. Natl. Acad. Sci. U.S.A., 101, 10548, 10.1073/pnas.0404151101 · DOI
- Das, 2004, Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants, J. Med. Chem., 47, 2550, 10.1021/jm030558s · DOI · Paper page
- Das, 2005, Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors, Prog. Biophys. Mol. Biol., 88, 209, 10.1016/j.pbiomolbio.2004.07.001 · DOI · Paper page
- Guillemont, 2005, Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1, J. Med. Chem., 48, 2072, 10.1021/jm040838n · DOI
- Janssen, 2005, In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoetenyl]-2-6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-benzonitrile (R278474-rilpivirine), J. Med. Chem., 48, 1901, 10.1021/jm040840e · DOI · Paper page
- Ghosh, 1996, Alterations to the primer grip of P66 HIV-1 reverse transcriptase and their consequences for template–primer utilization, Biochemistry, 35, 8553, 10.1021/bi952773j · DOI · Paper page
- Ghosh, 1997, Mutating a conserved motif of the HIV-1 reverse transcriptase palm subdomain alters primer utilization, Biochemistry, 36, 5758, 10.1021/bi963045e · DOI
- Palaniappan, 1997, Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function, J. Biol. Chem., 272, 11157, 10.1074/jbc.272.17.11157 · DOI · Paper page
- Powell, 1997, Alanine-scanning mutations in the "primer grip" of P66 HIV-1 reverse transcriptase result in selective loss of RNA priming activity, J. Biol. Chem., 272, 13262, 10.1074/jbc.272.20.13262 · DOI · Paper page
- Gao, 1998, Effects of mutations in the polymerase domain on the polymerase, RNase H and strand transfer activities of human immunodeficiency virus type 1 reverse transcriptase, J. Mol. Biol., 277, 559, 10.1006/jmbi.1998.1624 · DOI
- Powell, 1999, Residues in the alphaH and alphaI helices of the HIV-1 reverse transcriptase thumb subdomain required for the specificity of RNase H-catalyzed removal of the polypurine tract primer, J. Biol. Chem., 274, 19885, 10.1074/jbc.274.28.19885 · DOI · Paper page
- Edward, 1988, Synthesis of new acylhydrazones as iron-chelating compounds, J. Chem. Eng. Data, 33, 538, 10.1021/je00054a044 · DOI · Paper page
- Clark, 1995, Crystallization of human immunodeficiency virus type 1 reverse transcriptase with and without nucleic acid substrates, inhibitors and an antibody Fab fragment, Methods Enzymol., 262, 171, 10.1016/0076-6879(95)62017-6 · DOI
- Carroll, 2000, Only a small fraction of purified hepatitis C RNA-dependent RNA polymerase is catalytically competent: Implications for viral replication and in vitro assays, Biochemistry, 39, 8243, 10.1021/bi991992s · doi:10.1021/bi991992s
- Parniak, 2003, A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity, Anal. Biochem., 322, 33, 10.1016/j.ab.2003.06.001 · DOI
- Julias, 2001, Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase, J. Virol., 75, 6537, 10.1128/JVI.75.14.6537-6546.2001 · DOI
- Otwinowski, 2001, DENZO and SCALEPACK, 226
- Frisch, 1998, Gaussian 98
- Becke, 1993, Density-functional thermochemistry. III. The role of exact exchange, J. Chem. Phys., 98, 5648, 10.1063/1.464913 · DOI · Paper page
- Lee, 1988, Development of the Colle–Salvetti correlation-energy formula into a functional of the electron density, Phys. Rev. B: Condens. Matter, 37, 785, 10.1103/PhysRevB.37.785 · DOI · Paper page
- Jacobson, 2004, A hierarchical approach to all-atom loop prediction, Proteins: Struct., Funct., Bioinf., 55, 351, 10.1002/prot.10613 · DOI · Paper page
- Gallicchio, 2004, AGBNP: an analytic implicit solvent model suitable for molecular dynamics simulations and high-resolution modeling, J. Comput. Chem., 25, 479, 10.1002/jcc.10400 · DOI · Paper page
- Navaza, 1994, AMoRe: an automated package for molecular replacement, Acta Crystallogr. A, 50, 157, 10.1107/S0108767393007597 · DOI · Paper page
- Jones, 1991, Improved experimental procedures for building protein models in electron-density maps and the location of errors in these models, Acta Crystallogr. A, 47, 110, 10.1107/S0108767390010224 · DOI · Paper page
- Brünger, 1998, Crystallography and NMR system: a new software suite for macromolecular structure determination, Acta Crystallogr. D, 54, 905, 10.1107/S0907444998003254 · DOI · Paper page
Cited by
Sarafianos, S. G., Marchand, B., Das, K., Himmel, D. M., Parniak, M. A., Hughes, S. H., & Arnold, E. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.10.071 · Cited by 535
Self-citationTian, F.-F., Jiang, F.-L., Han, X.-L., Xiang, C., Ge, Y.-S., Li, J.-H., Zhang, Y., Li, R., Ding, X.-L., & Liu, Y. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp105766n · Cited by 270
HIV‐1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design
Zhan, P., Chen, X., Li, D., Fang, Z., De Clercq, E., & Liu, X. (2013) · Medicinal Research Reviews · doi:10.1002/med.20241 · Cited by 192
RNase H activity: structure, specificity, and function in reverse transcription
Schultz, S. J., & Champoux, J. J. (2008) · Virus Research · doi:10.1016/j.virusres.2007.12.007 · Cited by 150
Menéndez-Arias, L., Sebastián-Martín, A., & Álvarez, M. (2017) · Virus Research · doi:10.1016/j.virusres.2016.12.019 · Cited by 123
HIV-1 ribonuclease H: structure, catalytic mechanism and inhibitors
Beilhartz, G. L., & Götte, M. (2010) · Viruses · doi:10.3390/v2040900 · Cited by 88
“E N-acyl hydrazones appear to bind to multiple binding sites depending on the specific inhibitor, including the RNase H domain and a site that overlaps the NNRTI binding pocket (DHBNH picture above) [88].”
BackgroundInfluentialChung, S., Himmel, D. M., Jiang, J.-K., Wojtak, K., Bauman, J. D., Rausch, J. W., Wilson, J. A., Beutler, J. A., Thomas, C. J., Arnold, E., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2000757 · Cited by 80
Self-citationLe Grice, S. F. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.389056 · Cited by 73
“Surprisingly, while demonstrating selectivity for RNase H function, x-ray crystallography has shown that dihydroxy benzoyl naphthyl hydrazone binds 50 Å from the active site, interacting with Trp-229 of the primer grip and Asp-186 of the DNA polymerase active site (61).”
BackgroundActive site and allosteric inhibitors of the ribonuclease H activity of HIV reverse transcriptase
Corona, A., Masaoka, T., Tocco, G., Tramontano, E., & Le Grice, S. F. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.178 · Cited by 54
Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity
Ilina, T., LaBarge, K., Sarafianos, S. G., Ishima, R., & Parniak, M. A. (2012) · Biology · doi:10.3390/biology1030521 · Cited by 54
Self-citationWang, L., Sarafianos, S. G., & Wang, Z. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00450 · Cited by 43
Self-citationRecent progress in the research of small molecule HIV-1 RNase H inhibitors
Cao, L., Song, W., Clercq, E., Zhan, P., & Liu, X. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140120121158 · Cited by 34
Desantis, J., Massari, S., Corona, A., Astolfi, A., Sabatini, S., Manfroni, G., Palazzotti, D., Cecchetti, V., Pannecouque, C., Tramontano, E., et al. (2020) · Molecules · doi:10.3390/molecules25051183 · Cited by 29
Corona, A., Onnis, V., Del Vecchio, C., Esposito, F., Cheng, Y.-C., & Tramontano, E. (2020) · Molecules · doi:10.3390/molecules25061338 · Cited by 19
“Site-directed mutagenesis experiments showed that compound 21 binds independently to two different allosteric sites previously described: S first pocket (pocket 1), contiguous with the NNRTI binding pocket, was described for hydrazones [35], isatines [41,42] and pyrazoles [40].”
BackgroundRetroviral RNase H: structure, mechanism, and inhibition
(2021) · The Enzymes · doi:10.1016/bs.enz.2021.07.007 · Cited by 13
Self-citationFois, B., Corona, A., Tramontano, E., Distinto, S., Maccioni, E., Meleddu, R., Caboni, P., Floris, C., & Cottiglia, F. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1887170 · Cited by 7
Metadata
- Authors
- Himmel, D. M., Sarafianos, S. G., Dharmasena, S., Hossain, M. M., McCoy-Simandle, K., Ilina, T., Clark, A. D., Knight, J. L., Julias, J. G., Clark, P. K., Krogh-Jespersen, K., Levy, R. M., Hughes, S. H., Parniak, M. A., & Arnold, E.
- Venue
- ACS Chemical Biology
- Publisher
- American Chemical Society (ACS)
- Published
- 2006-11-28
- Volume
- 1
- Issue
- 11
- Pages
- 702-712
- ISSN
- 1554-8929 (ISSN-L)
- 1554-8937
- OpenAlex
- W2030926399
- Cited by
- 140
- References
- 3
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.